Learn more about Peter Attia’s digital program
#297 – AMA #58: Iron: its role in health, testing methods, and strategies for preventing and managing iron deficiency
“I’ve seen a lot of cases of iron deficiency. I’ve seen a lot of cases of iron deficiency anemia. I can’t tell you I’ve seen one that isn’t attributable to some combination of … low iron in the diet, poor absorption, or blood loss.” —Peter Attia
The MIND diet on trial: can diet choices impact cognitive health?
The results were lackluster, but a closer look leaves room for other explanations
Reassessing the relationship between alcohol intake and cardiovascular disease risk
Mendelian randomization offers clearer insights than epidemiology or randomized trials to date
Could an antihypertensive drug have independent benefits for longevity?
A recent animal study indicates that the antihypertensive drug rilmenidine has impressive effects on lifespan, but without further evidence, this story seems like another “fountain of youth” myth.
#258 – AMA #48: Blood pressure—how to measure, manage, and treat high blood pressure
“If you care about your brain, if you care about your heart and if you care about your kidneys, you need low blood pressure. I think we can say that as confidently as we can say almost anything in medicine.” —Peter Attia
#252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting | Rhonda Patrick, Ph.D.
“My perspective has shifted as any scientist that’s following data should… When new data comes out, you have to reassess things.” —Rhonda Patrick
#251 – AMA #46: Optimizing brain health: Alzheimer’s disease risk factors, APOE, prevention strategies, and more
“The bottom line here is the earlier you were diagnosed with type 2 diabetes, the higher your risk of dementia.” —Peter Attia
#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.
“If everybody got truly optimal medical therapy, if we didn’t have barriers to using all these tools in everybody, I think this disease would largely be controlled.” —Ethan Weiss
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D.
“When you think of brain health, it’s not just the cognitive piece, but it’s the movement piece too.” ‒ Kellyann Niotis